Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M

Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M
May 24, 2021 at 11:03 am
Bob Azelby. (Eliem Photo)
New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round.
The pipeline: Founded in 2019, the company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures. Both are in Phase 2a clinical trials.
ETX-810 is described as an investigational non-opioid that uses the palmitoylethanolamide (PEA) pathway to influence neuroinflammation and pain signaling. ETX-155 is an neuroactive steroid that acts as a GABA

Related Keywords

Andrew Levin ,Bob Azelby ,Valerie Morisset ,Convergence Pharmaceuticals ,Capital Group ,Lundbeck ,Eliem Photo ,Eliem Therapeutics ,Juno Therapeutics ,Alder Biopharmaceuticals ,Seattle Based Juno ,Intermediate Capital Group ,Access Biotechnology ,Samlyn Capital ,Acorn Bioventures ,ஆண்ட்ரூ லெவின் ,வலேரி மோரிசெட் ,குவிதல் மருந்துகள் ,மூலதனம் குழு ,ஜூனோ சிகிச்சை ,ஆல்டர் உயிர் மருந்துகள் ,சீட்டில் அடிப்படையிலானது ஜூனோ ,இடைநிலை மூலதனம் குழு ,நுழைவு உயிரி தொழில்நுட்பவியல் ,